New hope for advanced cancer? first human trial of HS-20122 begins

NCT ID NCT06927570

Recruiting now Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called HS-20122 in people with advanced solid tumors who have no other treatment options. The study aims to find the safest dose and check for side effects. Up to 1,050 participants will receive the drug intravenously and be monitored closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20122 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or may cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Ethics Committee of Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.